Equine Metabolism of MK-0677: Understanding Detection in Horses
Background
The synthetic growth hormone secretagogue (GHS) MK-0677 is a potent orally active compound known to stimulate the release of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). While it has potential therapeutic applications, its use is prohibited in competitive sports, including equine racing, due to concerns about performance enhancement and fair play. Despite its known effects, there was a significant gap in understanding how horses metabolize MK-0677 and how long it remains detectable in their systems.
Results
The in vitro studies identified three primary phase I metabolites resulting from hydroxylation and N-demethylation. Following oral administration, MK-0677 was rapidly absorbed, reaching peak plasma concentrations within 2 hours. The parent compound was detectable in plasma for up to 48 hours. However, its metabolites showed significantly longer detection windows. > The most significant finding was the identification of a novel long-lived urinary metabolite, M3, which was detectable in urine for up to 10 days post-administration, a 5-fold increase in detection time compared to the parent compound in plasma. Overall, MK-0677 and its major metabolites were excreted predominantly via urine, with 75% of the administered dose recovered within 72 hours.
Why It Matters
This research provides crucial data on the metabolic fate and elimination profile of MK-0677 in horses, which is vital for anti-doping efforts. The identification of long-lived urinary metabolites significantly extends the detection window, making it more challenging for illicit users to evade detection. This information is crucial for developing robust anti-doping strategies and improving analytical methods in equine sports. Future steps include validating these findings in a larger cohort and exploring the potential for chronic administration studies to understand accumulation and longer-term detection.